EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Colchicine and the risk of major adverse cardiovascular events in patients with gout and Type 2 diabetes: A nationwide cohort study

Minjeong Jeon, Yongtai Cho iD, Sungho Bea, Wonkyoung You, Sung Kweon Cho, Seungho Ryu, Yoosoo Chang iD, Ju-Young Shin iD

Journal of Internal Medicine · 2025-12 · 298 (6) · 604-616

DOI: 10.1111/joim.70012 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Internal Medicine, online erschienen am 23.08.2025. Verfasst von Minjeong Jeon und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Sungkyunkwan University, Suwon, South Korea. Hauptthemen laut MEDLINE: Colchicine, Gout, Diabetes Mellitus, Type 2, Cardiovascular Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Food and Drug Safety, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Type 2 diabetes mellitus (T2DM) and gout are associated with an increased risk of cardiovascular events. Despite the approval for the secondary prevention of cardiovascular diseases by the United States Food and Drug Administration in 2023, evidence regarding the effectiveness of colchicine among T2DM population remains limited.

Objectives

We aimed to evaluate the association between the use of colchicine and the risk of major adverse cardiovascular events (MACE) among patients with gout and T2DM.

Methods

We conducted a nationwide, population‐based cohort study with active comparator, new‐user design using nationwide claims data of South Korea (2010–2022). Patients with T2DM and gout who initiated colchicine or non‐steroidal anti‐inflammatory drugs (NSAIDs) from 2011 to 2022 were included. The primary outcome was MACE (myocardial infarction, ischemic stroke, and cardiovascular death). Secondary outcomes were each individual components of primary outcome and hospitalization due to heart failure. As‐treated approach with 30‐day grace period was applied.

Results

Before propensity score (PS) matching, 13,019 colchicine users and 111,594 NSAIDs users were included in the study cohort (mean age, 65.5 vs. 62.9; 35.0% vs. 29.8% female). After 1:2 PS matching, 12,908 colchicine users and 25,816 NSAIDs users remained (mean age, 65.7 vs. 65.7 years; 35.2% vs. 35.1% female). The PS‐matched hazard ratio for MACE was 0.94 (95% confidence interval 0.65–1.36), and all secondary outcomes also resulted in null findings.

Conclusions

Use of colchicine does not significantly reduce the risk of MACE compared with NSAIDs in a real‐world population with T2DM and gout in South Korea between 2011 and 2022.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ColchicineGoutDiabetes Mellitus, Type 2Cardiovascular DiseasesGout SuppressantsHumansMaleFemaleAgedMiddle AgedRepublic of KoreaCohort StudiesAnti-Inflammatory Agents, Non-SteroidalRisk Factors

Stichwörter der Autor:innen

Type 2 diabetescardiovascular eventscolchicinegout

Substanzen

ColchicineGout SuppressantsAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.
  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Pharmacology, Ajou University School of Medicine, Suwon, South Korea.
  • Center for Cohort Studies, Total Healthcare Center, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Department of Occupational and Environmental Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea.

ORCID-Profile: Yongtai Cho, Yoosoo Chang, Ju-Young Shin

Förderung

  • Ministry of Food and Drug Safety
  • National Research Foundation of Korea

Zitieren

APA

Jeon, M., Cho, Y., Bea, S., You, W., Cho, S. K., Ryu, S., Chang, Y., & Shin, J. Y. (2025). Colchicine and the risk of major adverse cardiovascular events in patients with gout and Type 2 diabetes: A nationwide cohort study. Journal of Internal Medicine, 298(6), 604-616. https://doi.org/10.1111/joim.70012

Vancouver

Jeon M, Cho Y, Bea S, You W, Cho SK, Ryu S, et al. Colchicine and the risk of major adverse cardiovascular events in patients with gout and Type 2 diabetes: A nationwide cohort study. Journal of Internal Medicine. 2025;298(6):604-616. doi:10.1111/joim.70012

BibTeX
@article{Jeon2025,
  author = {Jeon, Minjeong and Cho, Yongtai and Bea, Sungho and You, Wonkyoung and Cho, Sung Kweon and Ryu, Seungho and Chang, Yoosoo and Shin, Ju-Young},
  title = {Colchicine and the risk of major adverse cardiovascular events in patients with gout and Type 2 diabetes: A nationwide cohort study},
  journal = {Journal of Internal Medicine},
  year = {2025},
  volume = {298},
  number = {6},
  pages = {604--616},
  doi = {10.1111/joim.70012}
}
Kostenlos starten →